Exalgo is a brand-name, extended-release form of hydromorphone, a powerful opioid painkiller. It was designed specifically for people with chronic moderate to severe pain who already take opioids regularly and need around-the-clock relief. The brand has been discontinued in the U.S., though generic extended-release hydromorphone may still be available.
How Exalgo Works
Hydromorphone, the active ingredient in Exalgo, is a potent opioid that binds tightly to mu-opioid receptors in the brain and spinal cord. These receptors control pain signaling, and when hydromorphone activates them, they reduce the perception of pain while also producing sedation and, in some cases, euphoria. Hydromorphone binds to these receptors more strongly than many other common opioids, including morphine, oxycodone, and fentanyl. In terms of raw potency, it takes only about 2 mg of oral hydromorphone to match 10 mg of oral morphine, making it roughly five times stronger milligram for milligram.
What set Exalgo apart from immediate-release hydromorphone (sold under the brand name Dilaudid) was its delivery system. The tablet used osmotic-controlled release technology, which relies on water absorption to push the drug out of the tablet at a steady rate. This created a constant, even flow of hydromorphone over a full 24-hour period, meaning you took one pill per day rather than multiple doses every few hours.
Who It Was Prescribed For
Exalgo was not a first-line painkiller. It was reserved for people who were already opioid-tolerant, meaning their bodies had adapted to regular opioid use and they needed continuous pain control that shorter-acting medications couldn’t provide on their own. Typical candidates included people with chronic conditions like severe low back pain, cancer-related pain, or other long-term pain syndromes that required uninterrupted opioid coverage.
Because the tablet delivered its full 24-hour dose through a controlled mechanism, it was never meant to be crushed, chewed, or dissolved. Doing so would release the entire dose at once, which could cause a fatal overdose. This was one of the most critical safety warnings on the label.
Common Side Effects
Clinical trials involving nearly 2,500 chronic pain patients paint a clear picture of what people experienced while taking Exalgo. The digestive system bore the brunt: constipation affected 31% of patients, nausea hit 28%, and vomiting occurred in 14%. These are typical opioid side effects, but the rates are notably high, reflecting both the drug’s potency and its around-the-clock presence in the body.
Drowsiness was reported by 15% of patients, and about 11% experienced dizziness or general fatigue. Headaches affected 12%. Less common but still frequent effects included itching (8%), excessive sweating (6%), dry mouth (5%), swelling in the hands or feet (5%), decreased appetite (6%), and insomnia (7%).
Some patients also reported mood-related changes. Anxiety occurred in about 4% and depression in 3%. Shortness of breath, a concerning side effect with any opioid because of the risk of slowed breathing, was reported in 3% of patients across clinical studies.
Dependence and Withdrawal
Like all opioids, Exalgo carries a significant risk of physical dependence. Your body adjusts to the drug’s presence over time, and stopping suddenly can trigger withdrawal symptoms. In clinical trials, withdrawal syndrome was reported in about 2% of all patients studied. During one controlled trial focused on low back pain, withdrawal symptoms appeared in 10% of patients on Exalgo and 12% of those switched to placebo, illustrating how quickly the body can become reliant on steady opioid levels.
Tolerance is also a concern. Over weeks to months, the same dose may become less effective at controlling pain, which can lead to dose increases and a deepening cycle of dependence. This is one reason Exalgo was only prescribed to people already established on opioid therapy, where the risks were weighed against the realities of ongoing severe pain.
How Opioid Switching Works
When a prescriber moved someone from another opioid to Exalgo, they couldn’t simply do a straight mathematical conversion. While potency tables exist (hydromorphone is roughly five times more potent than morphine by mouth), switching opioids in practice requires a built-in safety margin. The standard approach is to reduce the calculated equivalent dose by 25% to 50%, then adjust gradually based on how the person responds. For patients on very high opioid doses, elderly patients, or those switching because of intolerable side effects, a reduction of at least 50% from the calculated dose is typical.
This careful approach reflects the fact that different opioids affect individuals differently. Two drugs with theoretically equal potency can produce very different effects in the same person, so close monitoring during any transition period is essential.
Safety Program and Regulations
Exalgo fell under the FDA’s Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS), a safety program that applies to all opioid painkillers prescribed for outpatient use. The program requires pharmaceutical manufacturers to provide training for prescribers, make drug disposal mail-back envelopes available through pharmacies, and ensure patients receive a Medication Guide every time their prescription is filled. These measures aim to reduce misuse, accidental exposure (particularly in children), and improper disposal.
Current Availability
The Exalgo brand name has been discontinued in the United States. Generic versions of extended-release hydromorphone may still be available, depending on FDA approvals and manufacturer production. If you were previously prescribed Exalgo or are seeing it mentioned in your medical records, the active drug (hydromorphone) remains widely used in other formulations, both immediate-release tablets and injectable forms. Your prescriber can determine whether a generic equivalent or an alternative long-acting opioid is appropriate for your situation.